---
title: 'Stem cell transplantation for ALL: you''ve always got a donor, why not always
  use it?'
date: '2023-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38066901/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231210170626&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Hematopoietic stem cell transplantation (HSCT) represents a consolidated
  therapeutic strategy for high-risk pediatric acute lymphoblastic leukemia (ALL),
  offering the potential for curative treatment. This manuscript delves into the debate
  around the more universal application of HSCT for pediatric ALL in the modern era,
  considering the ubiquitous availability of suitable donors. In fact, despite significant
  advancements in chemotherapy, targeted therapy, and immunotherapy, a subset of ...
disable_comments: true
---
Hematopoietic stem cell transplantation (HSCT) represents a consolidated therapeutic strategy for high-risk pediatric acute lymphoblastic leukemia (ALL), offering the potential for curative treatment. This manuscript delves into the debate around the more universal application of HSCT for pediatric ALL in the modern era, considering the ubiquitous availability of suitable donors. In fact, despite significant advancements in chemotherapy, targeted therapy, and immunotherapy, a subset of ...